At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
This week, Biogen announced that the European Commission has approved TOFIDENCE, a tocilizumab biosimilar referencing Roche's ROACTEMRA. TOFIDENCE was approved by the FDA in September 2023.
This week, Biogen announced that the European
Commission has approved TOFIDENCE, a tocilizumab biosimilar
referencing Roche's ROACTEMRA. TOFIDENCE was approved by the FDA in September
2023.
TOFIDENCE is an intravenous formulation of an interleukin-6
receptor antagonist, and is approved for the treatment of moderate
to severe active rheumatoid arthritis, polyarticular juvenile
idiopathic arthritis, systemic juvenile idiopathic arthritis and
COVID-19. Under a 2021 licensing agreement between Biogen and
Bio-Thera, Biogen has exclusive regulatory, manufacturing, and
commercial rights to TOFIDENCE in all countries, except China.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
